Cardiac effects of muscarinic receptor antagonists used for voiding dysfunction.
about
Drug therapy of overactive bladder--what is coming next?How to treat the frail elderly: The challenge of multimorbidity and polypharmacyManaging therapeutic competition in patients with heart failure, lower urinary tract symptoms and incontinenceCardiovascular safety in refractory incontinent patients with overactive bladder receiving add-on mirabegron therapy to solifenacin (BESIDE)New developments in the management of overactive bladder: focus on mirabegron and onabotulinumtoxinA.Normative blood pressure and heart rate in pediatric spinal cord injury.Rationale for the use of anticholinergic agents in overactive bladder with regard to central nervous system and cardiovascular system side effects.Antimuscarinic treatment in overactive bladder: special considerations in elderly patients.Pharmacokinetics and toxicity of antimuscarinic drugs for overactive bladder treatment in females.β3-receptor agonists for overactive bladder--new frontier or more of the same?Cardiovascular effects of antimuscarinic agents in overactive bladder.Phase II drugs that target cholinergic receptors for the treatment of overactive bladder.Drugs for the overactive bladder: are there differences in persistence and compliance?Clinical pharmacology of functional disorders of the urogenital system.Variation in cardiovascular risk related to individual antimuscarinic drugs used to treat overactive bladder. A cohort study in the UK.
P2860
Q26780197-32541F38-CBE2-4A08-A390-D38241CC5EC4Q26822934-88FCFC4B-25C2-4B99-88BB-ADA176613C72Q27027072-EDBB79DE-1777-447D-9B1F-86D3C94DCBA0Q33835874-F943EEAD-D2D0-4C8E-AE53-2ACCDC320485Q36789948-0204A804-457A-4528-A1B0-5273182122ABQ36811409-DA4D147E-1798-4DB7-AF34-8FECABAC99AFQ37399563-F146928F-9E0C-434C-A9B0-6EC178E81BA8Q38020185-26788FAD-209F-49B0-9FCB-E3051EB9D3AEQ38032608-16A5CC72-6528-4493-A9FF-F8D6FD3D12F1Q38107167-34C3DF27-B594-4EF6-8DDF-28960A046075Q38116972-B61E1791-22DE-4C9F-BDC1-31D0A7C838D2Q38217760-41D4BB64-09B8-40D2-B4D4-5271B398C5D5Q42332340-AECDEEC8-C632-4D53-B068-DDE2501E48C0Q42876778-FE1112D3-511D-4989-9F1A-3C24C4DE4E6AQ53820501-0066AAB4-A06B-439C-A21B-0F4E435CA1C1
P2860
Cardiac effects of muscarinic receptor antagonists used for voiding dysfunction.
description
2011 nî lūn-bûn
@nan
2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Cardiac effects of muscarinic receptor antagonists used for voiding dysfunction.
@ast
Cardiac effects of muscarinic receptor antagonists used for voiding dysfunction.
@en
type
label
Cardiac effects of muscarinic receptor antagonists used for voiding dysfunction.
@ast
Cardiac effects of muscarinic receptor antagonists used for voiding dysfunction.
@en
prefLabel
Cardiac effects of muscarinic receptor antagonists used for voiding dysfunction.
@ast
Cardiac effects of muscarinic receptor antagonists used for voiding dysfunction.
@en
P2093
P2860
P1476
Cardiac effects of muscarinic receptor antagonists used for voiding dysfunction.
@en
P2093
Brian Olshansky
Karl-Erik Andersson
Lysanne Campeau
P2860
P304
P356
10.1111/J.1365-2125.2010.03813.X
P407
P577
2011-08-01T00:00:00Z